Journal article
Early Clinical Outcome With Concurrent Chemotherapy and Extended-Field, Intensity-Modulated Radiotherapy for Cervical Cancer
International journal of radiation oncology, biology, physics, v 68(1), pp 166-171
01 May 2007
PMID: 17321070
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Purpose: To assess the early clinical outcomes with concurrent cisplatin and extended-field intensity-modulated radiotherapy (EF-IMRT) for carcinoma of the cervix.
Methods and Materials: Thirty-six patients with Stage IB2–IVA cervical cancer treated with EF-IMRT were evaluated. The pelvic lymph nodes were involved in 19 patients, and of these 19 patients, 10 also had para-aortic nodal disease. The treatment volume included the cervix, uterus, parametria, presacral space, upper vagina, and pelvic, common iliac, and para-aortic nodes to the superior border of L1. Patients were assessed for acute toxicities according to the National Cancer Institute Common Toxicity Criteria for Adverse Events, version 3.0. All late toxicities were scored with the Radiation Therapy Oncology Group late toxicity score.
Results: All patients completed the prescribed course of EF-IMRT. All but 2 patients received brachytherapy. Median length of treatment was 53 days. The median follow-up was 18 months. Acute Grade ≥3 gastrointestinal, genitourinary, and myelotoxicity were seen in 1, 1, and 10 patients, respectively. Thirty-four patients had complete response to treatment. Of these 34 patients, 11 developed recurrences. The first site of recurrence was in-field in 2 patients (pelvis in 1, pelvis and para-aortic in 1) and distant in 9 patients. The 2-year actuarial locoregional control, disease-free survival, overall survival, and Grade ≥3 toxicity rates for the entire cohort were 80%, 51%, 65%, and 10%, respectively.
Conclusion: Extended-field IMRT with concurrent chemotherapy was tolerated well, with acceptable acute and early late toxicities. The locoregional control rate was good, with distant metastases being the predominant mode of failure. We are continuing to accrue a larger number of patients and longer follow-up data to further extend our initial observations with this approach.
Metrics
Details
- Title
- Early Clinical Outcome With Concurrent Chemotherapy and Extended-Field, Intensity-Modulated Radiotherapy for Cervical Cancer
- Creators
- Sushil Beriwal - Department of Radiation Oncology, Pittsburgh, PAGregory N. Gan - University of PittsburghDwight E. Heron - Department of Radiation Oncology, Pittsburgh, PARaj N. Selvaraj - Department of Radiation Oncology, Pittsburgh, PAHayeon Kim - Department of Radiation Oncology, Pittsburgh, PARon Lalonde - Drug Development and DiscoveryJoseph L. Kelley - UPMC Hillman Cancer CenterRobert P. Edwards - UPMC Hillman Cancer Center
- Publication Details
- International journal of radiation oncology, biology, physics, v 68(1), pp 166-171
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Radiation Oncology (and Nuclear Medicine)
- Web of Science ID
- WOS:000246046000022
- Scopus ID
- 2-s2.0-34247156162
- Other Identifier
- 991021897264304721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Oncology
- Radiology, Nuclear Medicine & Medical Imaging